Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

Jesús F. San Miguel, Vânia Hungria, Sung‐Soo Yoon, +42

The Lancet Oncology

Hematological MalignancyDouble-blind Phase 3MedicineDexamethasone Versus PlaceboHematology +7

Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial

Simon Bowman, Robert I. Fox, Thomas Dörner, +13

The Lancet

Rheumatoid DisorderRheumatologyAutoimmune DiseaseSjögren’s SyndromePhase 2B +10

Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed and Refractory Multiple Myeloma

Jesús F. San Miguel, Paul G. Richardson, Andreas Günther, +11

Journal of Clinical Oncology

Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial

Jesús F. San Miguel, Vânia Hungria, Sung‐Soo Yoon, +17

The Lancet Haematology

Hematological MalignancyOncologyOverall SurvivalRelapsed Multiple MyelomaHematology +5

Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment

Paul G. Richardson, Vânia Hungria, Sung‐Soo Yoon, +18

Blood

Inhibitory effect of NPY on the picrotoxin-induced activity in the hippocampus: a behavioural and electrophysiological study

Maria Śmiałowska, M Bijak, Monika Sopala, +1

Neuropeptides

Behavioral NeuroscienceNeurophysiologyElectrophysiological StudyPhysiologyMedicine +10

Chronic cerebral hypoperfusion in the rat enhances age-related deficits in spatial memory

Monika Sopala, Wojciech Danysz

Journal of Neural Transmission

Cognitive ScienceAgingBrain FunctionNeurophysiologyChronic Cerebral Hypoperfusion +12

Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study

Benjamin A. Fisher, Xavier Mariette, Athena Papas, +16

The Lancet

RheumatologySubcutaneous IscalimabWeek 24Phase 2BClinical Trials +4

Middle cerebral artery occlusion produces secondary, remote impairment in hippocampal plasticity of rats – involvement of N-methyl-d-aspartate receptors?

Monika Sopala, Tadeusz Frankiewicz, Chris G. Parsons, +1

Neuroscience Letters

Synaptic PlasticityNeurobiology Of DiseaseNeurophysiologyHippocampal PlasticityVascular Cognitive Disorder +10

Patient‐reported outcomes of multiple myeloma patients treated with panobinostat after ≥2 lines of therapy based on the international phase 3, randomized, double‐blind, placebo‐controlled <scp>PANORAMA</scp>‐1 trial

Paul G. Richardson, Robert Schlossman, Anuja Roy, +4

British Journal of Haematology